Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05305287RecruitingPhase 4
Measuring liver energy use in people with diabetes and fatty liver disease
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
San Antonio, TexasAges 18–80 - NCT05248555Recruiting
Study of point-of-care hepatitis C testing in adults
This study collects basic information from adults who already had a quick, on-site hepatitis C (HCV) test. It aims to improve how point-of-care testing is done and documented, which may lead to faster follow-up and care.
Sydney, New South WalesAges 18 years+ - NCT05042544Recruiting
Testing program for people at risk of hepatitis C
This trial studies point-of-care (on-site) testing to find hepatitis C in adults who are at higher risk. If hepatitis C is found, earlier detection can help you get connected to care sooner.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT05030571Recruiting
Plasma adsorption for adults with liver failure in the ICU
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
BangkokAges 18 years+ - NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT04476563Recruiting
Study liver injury from checkpoint cancer immunotherapy
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
NottinghamAges 18 years+ - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT04162938Recruiting
Tablet app to help emergency patients learn about hepatitis C
This trial tests whether a patient-friendly electronic app given in the emergency department can increase what you know about hepatitis C and help you move to the next steps of care. It may be most helpful for people who are hepatitis C–positive but don’t yet have clear information about their status.
Baltimore, MarylandAges 18–100 - NCT04246970Enrolling by invitation
Training program before and after liver transplant
This trial studies a structured exercise and training program before and after liver transplantation to help people recover better. You may be able to benefit if you’re getting an elective liver transplant and can safely participate in the training plan.
Valencia, ValenciaAges 18 years+ - NCT04111692Recruiting
Watching foam treatment for cysts in autosomal polycystic disease
This study follows adults with inherited kidney and/or liver cysts that are causing symptoms to see how a foam sclerotherapy procedure may help and what outcomes happen over about a year. You may be eligible if you have a few sizable, specific-type cysts and can safely attend follow-up visits.
Rochester, MinnesotaAges 18–100 - NCT03884075RecruitingPhase 2
Semaglutide study for fatty liver and how sugar affects the liver
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Bethesda, MarylandAges 18–100 - NCT03383419RecruitingPhase 2
Hepatitis C–safe antiviral plan for heart transplant recipients
This Phase 2 trial tests giving newer hepatitis C medicines in a careful way to people getting a heart transplant who currently do not have hepatitis C in their blood. The goal is to lower hepatitis C infection risk from donated organs while keeping transplant outcomes safe.
Los Angeles, CaliforniaAges 18–90 - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT03845205Recruiting
Liver transplant timing study for alcohol-related liver disease
This study compares early versus standard liver transplant timing for people whose liver illness was caused by alcohol use. It looks at treatment outcomes to see which approach helps patients do better.
Baltimore, MarylandAges 18 years+ - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT03175471Recruiting
MRI study of blood-vessel and tissue signs in child liver disease
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
Cincinnati, OhioAges 6–23 - NCT03135886Recruiting
Testing for HIV in opioid treatment programs
This project studies how to improve offering and completing HIV (and hepatitis C) tests in opioid treatment programs. It may help increase timely follow-up and linkage to care when results are positive.
New York, New YorkAges 18 years+ - NCT02417740Recruiting
Study of the natural course of noncirrhotic portal hypertension
This study follows people with noncirrhotic portal hypertension (NCPH) or people at risk for it to better understand how the condition progresses over time. It does not sound like a medication trial—more like careful monitoring to learn what happens in different people.
Bethesda, MarylandAges 12–100 - NCT01280825Recruiting
Testing how to use genetic medicine results in routine care
This study looks at how to put genetic testing results (pharmacogenomics) into regular doctor care. It aims to see whether using the results helps doctors choose safer, better-matched medications.
Chicago, IllinoisAges 18 years+ - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT01401998Recruiting
Study collecting information from people with ARPKD
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
Washington D.C., District of ColumbiaAges Up to 18 years
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.